Continuum of Renin-Independent Aldosteronism in Normotension

Hypertension

Volumn 69, Issue 5, 2017, Pages 950-956

  Baudrand, Rene ^a   Guarda, Francisco J ^a   Fardella, Carlos ^a   Hundemer, Gregory ^b   Brown, Jenifer ^b   Williams, Gordon ^b   Vaidya, Anand ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

aldosterone; hypertension; normotensive; potassium; primary aldosteronism; renin

Indexed keywords

ALDOSTERONE; ANGIOTENSIN II; MINERALOCORTICOID RECEPTOR; POTASSIUM; RENIN; SODIUM;

ADULT; ALDOSTERONE RELEASE; ALDOSTERONE URINE LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL PROTOCOL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; KIDNEY PLASMA FLOW; MAJOR CLINICAL STUDY; MALE; PLASMA RENIN ACTIVITY; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SODIUM URINE LEVEL; BLOOD; BLOOD FLOW; DRUG EFFECTS; HYPERALDOSTERONISM; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULARIZATION;

ADULT; ALDOSTERONE; ANGIOTENSIN II; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYPERALDOSTERONISM; KIDNEY; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; RENIN;

EID: 85015193873     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.116.08952     Document Type: Article

References (16)

1. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF Jr, The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016 101 1889 1916. doi: 10.1210/jc.2015-4061.
2. Xanthakis V, Vasan RS, Aldosterone and the risk of hypertension. Curr Hypertens Rep 2013 15 102-107. doi: 10.1007/s11906-013-0330-y.
3. Wu VC, Wang SM, Chang CH, Hu YH, Lin LY, Lin YH, Chueh SC, Chen L, Wu KD, Long term outcome of Aldosteronism after target treatments. Sci Rep 2016 6 32103. doi: 10.1038/srep32103.
4. Piaditis G, Markou A, Papanastasiou L, Androulakis II, Kaltsas G, Progress in aldosteronism: a review of the prevalence of primary aldosteronism in pre-hypertension and hypertension. Eur J Endocrinol 2015 172 R191-R203. doi: 10.1530/EJE-14-0537.
5. Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE, Primary aldosteronism and hypertensive disease. Hypertension 2003 42 161-165. doi: 10.1161/01.HYP.0000079505.25750.11.
6. Baudrand R, Guarda FJ, Torrey J, Williams G, Vaidya A, Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab 2016 101 3989-3996. doi: 10.1210/jc.2016-1963.
7. Markou A, Pappa T, Kaltsas G, Gouli A, Mitsakis K, Tsounas P, Prevoli A, Tsiavos V, Papanastasiou L, Zografos G, Chrousos GP, Piaditis GP, Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: a very high odds ratio for progression into arterial hypertension. J Clin Endocrinol Metab 2013 98 1409 1416. doi: 10.1210/jc.2012-3353.
8. Nishimoto K, Nakagawa K, Li D, Kosaka T, Oya M, Mikami S, Shibata H, Itoh H, Mitani F, Yamazaki T, Ogishima T, Suematsu M, Mukai K, Adrenocortical zonation in humans under normal and pathological conditions. J Clin Endocrinol Metab 2010 95 2296-2305. doi: 10.1210/jc.2009-2010.
9. Nishimoto K, Tomlins SA, Kuick R, Cani AK, Giordano TJ, Hovelson DH, Liu CJ, Sanjanwala AR, Edwards MA, Gomez-Sanchez CE, Nanba K, Rainey WE, Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci USA 2015 112 E4591-E4599. doi: 10.1073/pnas.1505529112.
10. Baudrand R, Pojoga LH, Vaidya A, Garza AE, Vöhringer PA, Jeunemaitre X, Hopkins PN, Yao TM, Williams J, Adler GK, Williams GH, Statin use and adrenal aldosterone production in hypertensive and diabetic subjects. Circulation 2015 132 1825-1833. doi: 10.1161/CIRCULATIONAHA.115.016759.
11. Vaidya A, Underwood PC, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH, Adler GK, Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension 2013 61 886-893. doi: 10.1161/HYPERTENSIONAHA.111.00662.
12. Nishizaka MK, Pratt-Ubunama M, Zaman MA, Cofield S, Calhoun DA, Validity of plasma aldosterone-to-renin activity ratio in African American and white subjects with resistant hypertension. Am J Hypertens 2005 18 805-812. doi: 10.1016/j.amjhyper.2005.01.002.
13. Eudy RJ, Sahasrabudhe V, Sweeney K, Tugnait M, King-Ahmad A, Near K, Loria P, Banker ME, Piotrowski DW, Boustany-Kari CM, The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism. J Transl Med 2011 9 180. doi: 10.1186/1479-5876-9-180.
14. Brown JM, Underwood PC, Ferri C, Hopkins PN, Williams GH, Adler GK, Vaidya A, Aldosterone dysregulation with aging predicts renal vascular function and cardiovascular risk. Hypertension 2014 63 1205-1211. doi: 10.1161/HYPERTENSIONAHA.114.03231.
15. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, Benjamin EJ, Levy D, Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004 351 33 41. doi: 10.1056/NEJMoa033263.
16. Lalli E, Barhanin J, Zennaro MC, Warth R, Local Control of Aldosterone Production and Primary Aldosteronism. Trends Endocrinol Metab 2016 27 123-131. doi: 10.1016/j.tem.2016.01.003.